SCHEMBL10169901

SCHEMBL10169901

Cc1cc2c([nH]c3ccccc32)c(C)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.60
KDM4E B2RXH2 4/20 0.58
MAPT P10636 4/20 0.58
LMNA P02545 3/20 0.58
ALDH1A1 P00352 2/20 0.58
HPGD P15428 2/20 0.58
MAPK1 P28482 2/20 0.58
HSD17B10 Q99714 2/20 0.58
TP53 P04637 1/20 0.58
HTT P42858 1/20 0.58
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
GABRP O00591 1/20 0.57
GABRD O14764 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
GABRA1 P14867 1/20 0.57
TSHR P16473 1/20 0.57
GABRB1 P18505 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756559 1.00 DYRK1A (0.60) DYRK1AKDM4EMAPTLMNAALDH1A1
SCHEMBL10708983 0.83 MAPT (0.59) KDM4EMAPTLMNAALDH1A1HPGD
SCHEMBL30492917 0.83 KDM4E (0.49) DYRK1AKDM4EMAPTLMNAALDH1A1
SCHEMBL9313465 0.83 MAPT (0.56) KDM4EMAPTLMNAALDH1A1HPGD
SCHEMBL28667621 0.83 MAPT (0.56) KDM4EMAPTLMNAALDH1A1HPGD
SCHEMBL29817742 0.80 MAPT (0.53) DYRK1AKDM4EMAPTLMNAALDH1A1
SCHEMBL16892195 0.79 DYRK1A (0.65) DYRK1AKDM4EMAPTLMNAALDH1A1
SCHEMBL3741515 0.79 DYRK1A (0.46) DYRK1AKDM4EMAPTLMNAALDH1A1
SCHEMBL18214992 0.79 MAPT (0.52) KDM4EMAPTLMNAALDH1A1HPGD
SCHEMBL29630396 0.79 MAPT (0.56) KDM4EMAPTLMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3792262-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2026-04-15 EP disclosed
US-20250333412-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2025-10-30 US disclosed
US-12275733-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2025-04-15 US disclosed
US-20240182469-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2024-06-06 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
US-20200095242-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2020-03-26 US disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed
US-20160326166-A1 ß-CARBOLINE, DIHYDRO-ß-CARBOLINE AND TETRAHYDRO-ß-CARBOLINE ALKALOID DERIVATIVES AND PREPARATION METHODS SAME AND USE IN ASPECTS OF PREVENTING AND TREATING PLANT VIRUSES, FUNGICIDES AND INSECTICIDES NANKAI UNIVERSITY (CN) 2016-11-10 US disclosed
US-8110570-B2 Modulators of acetyl-coenzyme A carboxylase and methods of use thereof CROPSOLUTION, INC. (US) 2012-02-07 US disclosed
US-8110570-B2 Modulators of acetyl-coenzyme A carboxylase and methods of use thereof CROPSOLUTION, INC. (US) 2012-02-07 US disclosed
US-20100009982-A1 Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof CROPSOLUTION, INC. 2010-01-14 US disclosed
US-20100009982-A1 Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof CROPSOLUTION, INC. 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885KDM4E 706/4885MAPT 4099/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885KDM4E 706/4885MAPT 4099/4885
US-20160326166-A1 ß-CARBOLINE, DIHYDRO-ß-CARBOLINE AND TETRAHYDRO-ß-CARBOLINE ALKALOID DERIVATIVES AND PREPARATION METHODS SAME AND USE IN ASPECTS OF PREVENTING AND TREATING PLANT VIRUSES, FUNGICIDES AND INSECTICIDES DDT, NOTUM, DDAH1 DYRK1A 2918/4885KDM4E 1695/4885MAPT 1698/4885
US-20100009982-A1 Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof ACACA, ACAT1, ACACB DYRK1A 4737/4885KDM4E 2462/4885MAPT 1108/4885
US-20200095242-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 DYRK1A 493/4885KDM4E 706/4885MAPT 4099/4885
US-20240182469-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 DYRK1A 493/4885KDM4E 706/4885MAPT 4099/4885
US-12275733-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 DYRK1A 493/4885KDM4E 706/4885MAPT 4099/4885
US-20250333412-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 DYRK1A 498/4885KDM4E 723/4885MAPT 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.